Most Popular in:
Inflammation and Aging
By: Marie Alice Dibon, PharmD
Posted: March 7, 2011, from the March 2011 issue of GCI Magazine.
page 5 of 6The increase in intracellular ROS also increases the level of oxidized proteins inside the cells. Because the proteasome, also a victim of aging, is less active, these damaged proteins stay around longer. Many of these being antioxidant enzymes; the cell then suffers a double damage: loss of efficacy of its normal antioxidative arsenal and added oxidation phenomena due to the release of free radicals by these non eliminated oxidized proteins.
“What this shows us, is that inflamm-aging is a self-worsening phenomenon, which, if not addressed, can only lead to greater damage than it started with,” says Daniel Maes, specialist in the field, industry consultant and former senior vice president of R&D for The Estée Lauder Companies. [He is featured as one of the 2011 “People to Know” in the January/February issue of GCI magazine]. “Just like any chronic inflammation phenomenon, it will not be very obvious and creep into real damage that is then very difficult to fight once it is finally apparent,” he says.
In order to fight inflamm-aging, both internal and external aspects of the phenomenon must be addressed:
- Fighting the external damage by using anti-inflammatory compounds (antiPGE2, anti IL1, anti IL6, anti PGE2) and antioxidant compounds.
- Fighting mitochondrial damage and protecting mtDNA with products such as the Chondricare from ISP, while also fighting the generation of ROS inside the mitochondria with compounds such as the EuKarion-134 (used in both Lauder and Clinique products), which help the primary antioxidant reactivation.
- Fighting protein oxidation by the reactivation of proteasome (with products such as Prolixir S20 from ISP, or Magassane from Soliance).
1. S Salvioli, M Capri, S Valensin, P Tieri, D Monti, E Ottaviani, C Franceschi, Inflamm-Aging, Cytokines and Aging: State of the Art, New Hypotheses on the Role of Mitochondria and New Perspectives from Systems Biology, Current Pharmaceutical Design, 12 24 3161–3171 (Aug 2006)